The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481].

FIELD Study Investigators.

Cardiovasc Diabetol. 2004 Dec 1;3:9.

PMID: 15571637 [PubMed]

Related Articles Free article in PMC

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420.

PMID: 16310551 [PubMed - indexed for MEDLINE]

Related Articles

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A; FIELD Study Investigators.

Cardiovasc Diabetol. 2005 Aug 22;4:13.

PMID: 16111499 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

Fibrates after the FIELD study: Some answers, more questions.

Wierzbicki AS.

Diab Vasc Dis Res. 2006 Dec;3(3):166-71. Review.

PMID: 17160911 [PubMed - indexed for MEDLINE]

Related Articles

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID: 17599422 [PubMed - indexed for MEDLINE]

Related Articles

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Nesto RW.

Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.

PMID: 16259526 [PubMed - indexed for MEDLINE]

Related Articles

A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?

Steiner G.

Treat Endocrinol. 2005;4(5):311-7. Review.

PMID: 16185099 [PubMed - indexed for MEDLINE]

Related Articles

Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2004 Dec 1;3:10.

PMID: 15574199 [PubMed]

Related Articles Free article in PMC

Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.

Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.

Clin Ther. 2004 Oct;26(10):1599-607.

PMID: 15598476 [PubMed - indexed for MEDLINE]

Related Articles

FIELDS of dreams, fields of tears: a perspective on the fibrate trials.

Wierzbicki AS.

Int J Clin Pract. 2006 Apr;60(4):442-9. Review.

PMID: 16620358 [PubMed - indexed for MEDLINE]

Related Articles

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Keating GM, Croom KF.

Drugs. 2007;67(1):121-53. Review.

PMID: 17209672 [PubMed - indexed for MEDLINE]

Related Articles

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J.

Diabetes Care. 2005 May;28(5):1151-7.

PMID: 15855581 [PubMed - indexed for MEDLINE]

Related Articles

Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.

Vergès B.

Curr Opin Lipidol. 2006 Dec;17(6):653-8. Review.

PMID: 17095910 [PubMed - indexed for MEDLINE]

Related Articles

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.

Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM Jr.

Ann Intern Med. 2005 Jan 18;142(2):95-104. Summary for patients in: Ann Intern Med. 2005 Jan 18;142(2):I46.

PMID: 15657157 [PubMed - indexed for MEDLINE]

Related Articles

[Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes]

Radermecker RP, Scheen AJ.

Rev Med Liege. 2005 Dec;60(12):957-61. French.

PMID: 16457397 [PubMed - indexed for MEDLINE]

Related Articles

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).

Knopp RH, d'Emden M, Smilde JG, Pocock SJ.

Diabetes Care. 2006 Jul;29(7):1478-85.

PMID: 16801565 [PubMed - indexed for MEDLINE]

Related Articles

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins.

De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, Valentini U, Nicolucci A; ACCEPT-D Study Group.

Trials. 2007 Aug 28;8:21.

PMID: 17725825 [PubMed - in process]

Related Articles Free article in PMC

The collaborative atorvastatin diabetes study: preliminary results.

Owen OG.

Int J Clin Pract. 2005 Jan;59(1):121-3.

PMID: 15707477 [PubMed - indexed for MEDLINE]

Related Articles

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID: 15669880 [PubMed - indexed for MEDLINE]

Related Articles

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators.

Drugs. 2004;64 Suppl 2:43-60.

PMID: 15765890 [PubMed - indexed for MEDLINE]

Related Articles